Liso-cel cost-effective for second-line relapsed/refractory lymphoma

Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell remedy, is cost-effective for second-line diffuse giant B-cell lymphoma (DLBCL) remedy, in keeping with a examine revealed on-line Dec. 28 in Blood Advances.

Jee H. Choe, from the College of Southern California in Los Angeles, and colleagues evaluated the cost-effectiveness of liso-cel versus platinum-based chemotherapy adopted by autologous hematopoietic stem cell transplantation for relapsed and refractory DLBCL utilizing a partitioned survival mannequin with normal parametric capabilities over a lifetime horizon. The mannequin employed a hypothetical cohort of DLBCL sufferers, aged 60 years (57 p.c male), with refractory DLBCL or who relapsed early, inside 12 months of preliminary remedy.

The researchers discovered that for the consultant cohort, the incremental cost-effectiveness ratio of liso-cel was $99,669 per quality-adjusted life yr (QALY) from a well being care sector perspective and $68,212 per QALY from a societal perspective, confirming cost-effectiveness on the threshold of $100,000 per QALY. Liso-cel surpassed this benchmark below sure eventualities however remained inside the acceptable vary of $150,000 per QALY in america.

“Our examine contributes novel insights to the increasing analysis on the financial and societal implications of CAR T-cell therapies,” the authors write. “It reaffirms the significance of evaluating CAR T-cell therapies past their rapid prices, emphasizing their long-term medical and societal impacts for a extra complete evaluation of their general worth.”

A number of authors disclosed ties to the pharmaceutical trade.

Copyright © 2024 HealthDay. All rights reserved.